Skip to main content

Illinois IGB

Paul Hergenrother

Dozens of potential new antibiotics discovered with free online app

November 19, 2019

A new web tool speeds the discovery of drugs to kill Gram-negative bacteria, which are responsible for the vast majority of antibiotic-resistant infections and deaths. The tool also offers insights into discrete chemical changes that can convert drugs that kill other bacteria into drugs to fight Gram-negative infections. The team proved the system works by modifying a Gram-positive drug and testing it against three different Gram-negative bacterial culprits in mouse sepsis. The drug was successful against each.


November 19, 2019


Related Articles

Cancer drug starts clinical trials in human brain-cancer patients

November 27, 2017

A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the brain. This phase Ib trial will determine if the experimental drug PAC-1 can be used safely in combination with a standard brain-cancer chemotherapy drug, temozolomide.


November 27, 2017


Related Articles

Cancer Drug Tested in Pet Dogs is Now Bound for Human Trials

July 20, 2013

Cancer Drug Tested in Pet Dogs is Now Bound for Human Trials

Thanks to a new $2 million investment, a drug that spurs cancer cells to self-destruct while sparing healthy cells is on the road to human clinical trials. The compound, known as PAC-1, has so far proven safe and has promising anti-cancer effects in cell culture, in mouse models of cancer and in pet dogs with spontaneously occurring lymphomas and osteosarcomas.


July 20, 2013


Related Articles

Paul Hergenrother: Finding New Targets by Way of Novel Pathways

December 17, 2010

While there are thousands of drugs on the market for human diseases, they only hit in the neighborhood of 200 targets, says Paul Hergenrother, professor of chemistry and a member of the Cellular Decision Mak­ing in Cancer (CDMC) Theme at the IGB. Many drugs aim at the same target and are either minor improvements or work in a different way. And, while there is some rationale for developing new drugs for old targets, Hergenrother has an entirely different goal.


December 17, 2010


Related Articles

Subscribe to Paul Hergenrother